Jim Gearhart

by Jim Gearhart

Week in Review (February 20, 2015)

Happy Friday, everyone.

CRO Quintiles will help the NFL study concussion injuries.

Lilly-coi talks about communicating with participants after a trial ends.

Patient groups recently rated ViiV Healthcare’s as the pharmaceutical company with the best corporate reputation. BioPharma Dive considers why.

The CDC reported that flu infections appear to have peaked for the season. This year’s vaccine proved less effective than in the past; the CDC’s summary says the vaccine reduced chances of the flu by 23 percent.

I enjoyed this blog entry about nutrition by Dr. David Katz. It considers the research behind health claims of paleo versus vegan diets.

FDA

The FDA has issued draft guidelines about clinical studies on treatments for alcoholism.

It also is looking for input about which biomarkers could speed drug research and support approvals. The FDA release can be found here.

The Center for Drug Evaluation and Research (CDER) has a new podcast, the Director’s Corner. In its first broadcast, Director Janet Woodcock discussed CDER’s accomplishments in 2014 and its goals for 2015. Review of the FDA’s first biosimilar topped the list of 2014 accomplishments. The audio and transcript are here.

NIH’s Images:

Here’s a striking and potentially illuminating image of cancer cells.

Tags: , , , , , ,